Bone-forming agents in the management of osteoporosis

Reginster, 1993 Riggs, 1998, A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men, Journal of Bone and Mineral Research, 13, 763, 10.1359/jbmr.1998.13.5.763 Christiansen, 1991, Estrogens, bone loss and preservation, Osteoporosis International, 1, 714 Reginster, 1987, 1-year controlled randomised trial of prevention of early postmenopausal bone loss with intranasal calcitonin, Lancet, 2, 1481, 10.1016/S0140-6736(87)92619-5 Reginster, 1995, Prevention of postmenopausal bone loss by rectal calcitonin, Calcified Tissue International, 56, 539, 10.1007/BF00298586 Hosking, 1996, Alendronate in the prevention of osteoporosis: EPIC study two-year results, Journal of Bone and Mineral Research, 11, 133 Mortensen, 1995, Prevention of early postmenopausal bone loss by risedronate: a two-year study, Journal of Bone and Mineral Research, 10, 140 Reginster, 1989, Prevention of postmenopausal bone loss by tiludronate, Lancet, 2, 1469, 10.1016/S0140-6736(89)92927-9 Reginster, 1993, Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis, Bone Miner, 23, 223, 10.1016/S0169-6009(08)80099-2 Reginster, 1996, Prévention de l'ostéoporose à Liège: le PIGEPS dix ans plus tard, Santé Publique, 2, 139 Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women. HipIntervention Program Study Group, The New England Journal of Medicine, 344, 333, 10.1056/NEJM200102013440503 Reginster, 2000, Randomized trial of the effect of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, Osteoporosis International, 11, 83, 10.1007/s001980050010 Delmas, 2002, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial, The Journal of Clinical Endocrinology and Metabolism, 87, 3609, 10.1210/jcem.87.8.8750 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, JAMA : The Journal of the American Medical Association, 282, 1344, 10.1001/jama.282.14.1344 Delmas, 2004, Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study, Osteoporosis International, 15, 792, 10.1007/s00198-004-1602-9 Reginster, 2006, Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study, Annals of the Rheumatic Diseases, 65, 654, 10.1136/ard.2005.044958 Stakkestad, 2008, Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension, Clinical Rheumatology, 10.1007/s10067-007-0824-6 Eisman, 2008, Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study, The Journal of Rheumatology, 35, 488 Lyles, 2007, Zoledronic acid and clinical fractures and mortality after hip fracture, The New England Journal of Medicine, 357, 1799, 10.1056/NEJMoa074941 Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, The New England Journal of Medicine, 356, 1809, 10.1056/NEJMoa067312 Recker, 2008, Effects of intravenous zoledronic acid once yearly on bone remodelling and bone structure, Journal of Bone and Mineral Research, 23, 6, 10.1359/jbmr.070906 Reginster, 1997, Parathyroid hormone in the treatment of involutional osteoporosis: back to the future, Osteoporosis International, 7, S163, 10.1007/BF03194365 Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, The New England Journal of Medicine, 344, 1434, 10.1056/NEJM200105103441904 Marcus, 2003, The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis, Journal of Bone and Mineral Research, 18, 18, 10.1359/jbmr.2003.18.1.18 Lindsay, 2004, Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1–34)) in postmenopausal women with osteoporosis, Archives of Internal Medicine, 164, 2024, 10.1001/archinte.164.18.2024 Prince, 2005, Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment, Journal of Bone and Mineral Research, 20, 1507, 10.1359/JBMR.050501 Delmas, 2006, Fracture Risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover, Bone, 39, 237, 10.1016/j.bone.2006.02.003 Jilka, 1999, Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone, The Journal of Clinical Investigation, 104, 371, 10.1172/JCI6610 Greenspan, 2007, Treatment of Osteoporosis with Parathyroid Hormone Study Group, Annals of Internal Medicine, 146, 326, 10.7326/0003-4819-146-5-200703060-00005 Shrader, 2005, Parathyroid hormone (1-84) and treatment of osteoporosis, The Annals of Pharmacotherapy, 39, 1511, 10.1345/aph.1G146 Hodsman, 2003, Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis, The Journal of Clinical Endocrinology and Metabolism, 88, 5212, 10.1210/jc.2003-030768 Hodsman, 2005, Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use, Endocrine Reviews, 26, 688, 10.1210/er.2004-0006 Reginster, 2002, Prevention of early postmenopausal bone loss by strontium ranelate: a randomized, two-year, double-blind, dose-ranging, placebo-controlled trial, Osteoporosis International, 13, 925, 10.1007/s001980200129 Meunier, 2002, Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial, The Journal of Clinical Endocrinology and Metabolismolism, 87, 2060 Reginster, 2002, Calcium-vitamin D supplementation in clinical trials of osteoporosis should be titrated on the basis of pre-study assessments, Osteoporosis International, 13, S24 Reginster, 2002, A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate Phase III program, Osteoporosis International, 13, S30 Meunier, 2002, Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis, Osteoporosis International, 13, O45 Meunier, 2004, The effect of strontium ranelate on the risk of vertebral fracture in Women with Post Menopausal Osteoporosis, The New England Journal of Medicine, 350, 459, 10.1056/NEJMoa022436 Reginster, 2005, Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study, The Journal of Clinical Endocrinology and Metabolism, 90, 2816, 10.1210/jc.2004-1774 Roux, 2006, Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors, Journal of Bone and Mineral Research, 21, 536, 10.1359/jbmr.060101 Seeman, 2006, Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older, Journal of Bone and Mineral Research, 21, 1113, 10.1359/jbmr.060404 Seeman, 2007, Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia, Journal of Bone and Mineral Research, 10.1359/jbmr.071105 Reginster, 2003, Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies, Osteoporosis International, 14, S56, 10.1007/s00198-002-1349-0 Bruyere, 2007, Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate, The Journal of Clinical Endocrinology and Metabolism, 92, 3076, 10.1210/jc.2006-2758 Bruyere, 2007, Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate, Current Medical Research and Opinion, 23, 3041, 10.1185/030079907X242818 Arlot, 2008, Histomorphometric and μ-CT Analysis of Bone Biopsies from Postmenopausal Osteoporotic Women Treated with Strontium Ranelate, Journal of Bone and Mineral Research, 23, 215, 10.1359/jbmr.071012 Shea, 2004, Calcium supplementation on bone loss in postmenopausal women, Cochranese of Systematic Reviews, 1, 10.1002/14651858.CD004526.pub2 Tas, 2003, Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update, Dermatology, 206, 353, 10.1159/000069956 Frost, 1979, Treatment of osteoporosis by manipulation of coherent bone cell populations, Clinical Orthopaedics and Related Research, 143, 227 Lindsay, 1997, Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis, Lancet, 350, 550, 10.1016/S0140-6736(97)02342-8 Cosman, 2001, Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal, Journal of Bone and Mineral Research, 16, 925, 10.1359/jbmr.2001.16.5.925 Lane, 1998, Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis, The Journal of Clinical Investigation, 102, 1627, 10.1172/JCI3914 Lane, 2000, Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial, Journal of Bone and Mineral Research, 15, 944, 10.1359/jbmr.2000.15.5.944 Ettinger, 2004, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate, Journal of Bone and Mineral Research, 19, 745, 10.1359/jbmr.040117 Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, The New England Journal of Medicine, 349, 1207, 10.1056/NEJMoa031975 Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, The New England Journal of Medicine, 349, 1216, 10.1056/NEJMoa035725 Khosla, 2003, Parathyroid hormone plus alendronate – A combination that does not add up, The New England Journal of Medicine, 349, 1277, 10.1056/NEJMe038143 Rittmaster, 2000, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate, The Journal of Clinical Endocrinology and Metabolism, 85, 2129 Rhee, 2004, Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats, Journal of Bone and Mineral Research, 19, 931, 10.1359/JBMR.040123